RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Results of Operations and Financial Condition
ITEM2.02
|
RESULTS OF OPERATIONS AND FINANCIAL CONDIDITIONS |
On January9, 2017, the Company issued a press release announcing
preliminary financial results for the year ended December31,
2016. A copy of the press release is attached as Exhibit 99.1 to
this current report.
The information in this Item2.02, and Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this current report shall not be incorporated
by reference into any registration statement or other document
filed with the Securities and Exchange Commission, whether filed
before or after the date hereof regardless of any general
incorporation language in any such filing, unless the registrant
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.
Forward-Looking Statements
Statements contained in this Current Report on Form 8-K regarding
matters that are not historical facts are forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such
forward-looking statements. Risks are described more fully in the
Companys filings with the Securities and Exchange Commission,
including without limitation the Companys most recent Quarterly
Report on Form 10-Q and other documents subsequently filed with
or furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this Current Report on
Form 8-K speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
ITEM9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
| 99.1 | Press release of Retrophin, Inc. dated January9, 2017. |
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1. RETROPHIN, INC. (NASDAQ:RTRX) Recent Trading Information
RETROPHIN, INC. (NASDAQ:RTRX) closed its last trading session up +0.40 at 19.72 with 566,276 shares trading hands.
